Company intelligence / Profile preview

AITRICS

Seoul, Seoul Special City / Seoul-si / Seoul Metropolitan City / 서울특별시, South Koreaaitrics.com ↗

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

The company’s flagship product VitalCare received regulatory approval from the South Korean Ministry of Food and Drug Safety in October 2022. It predicts patient deterioration such as sepsis and cardiac arrest within 4–6 hours using real-time monitoring of vital signs and lab data. It has been deployed in over 40 hospitals in Korea and is undergoing validation with Cleveland Clinic for US entry.

Therapeutic areas: OtherCardiovascularInfectious Diseases
Modalities: DeviceSoftware (AI-based clinical decision support)
Industry: Digital Health Medical Devices

Partnerships

Cleveland Clinic (clinical validation partner for US market entry)

Beyond the preview

Go deeper on AITRICS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AITRICS.

Explore the full profile